Previous studies have indicated a correlation between SERPINF2 with unfavorable outcomes in advanced serous ovarian cancer, and laboratory tests have confirmed its crucial involvement in tumor growth and spread (Huh et al., 2022). The gene discussed is SERPINF2; the disease is neoplasm.